<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">jofin</journal-id><journal-title-group><journal-title xml:lang="ru">Журнал инфектологии</journal-title><trans-title-group xml:lang="en"><trans-title>Journal Infectology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-6732</issn><publisher><publisher-name>IPO “АIDSSPbR"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.22625/2072-6732-2023-15-3-44-50</article-id><article-id custom-type="elpub" pub-id-type="custom">jofin-1540</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальное исследование</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Результаты оценки гемостаза методом тромбоэластографии у пациентов с COVID-19</article-title><trans-title-group xml:lang="en"><trans-title>The results of hemostasis assessment using thromboelastography in patients with COVID-19</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Городин</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Gorodin</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Городин Владимир Николаевич – заведующий кафедрой инфекционных болезней и эпидемиологии ФПК и ППС КубГМУ; главный врач ИБ № 2, доктор медицинских наук, профессор.</p><p>Краснодар; Сочи</p><p>тел.: 8(861)255-44-23</p></bio><bio xml:lang="en"><p>Krasnodar; Sochi</p></bio><email xlink:type="simple">vgorodin@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мойсова</surname><given-names>Д. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Moysova</surname><given-names>D. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мойсова Диана Леонидовна – профессор кафедры инфекционных болезней и эпидемиологии ФПК и ППС, доктор медицинских наук.</p><p>Краснодар</p><p>тел.: 8(861)255-44-23</p></bio><bio xml:lang="en"><p>Krasnodar</p></bio><email xlink:type="simple">moisova.di@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Суркова</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Surkova</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Суркова Анастасия Дмитриевна – ординатор 1 года кафедры инфекционных болезней и эпидемиологии ФПК и ППС.</p><p>Краснодар</p><p>тел.: 8(861)255-44-23</p></bio><bio xml:lang="en"><p>Krasnodar</p></bio><email xlink:type="simple">nastya@surkoff.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Кубанский государственный медицинский университет; Инфекционная больница № 2<country>Россия</country></aff><aff xml:lang="en">Kuban State Medical University; The infection hospital № 2<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Кубанский государственный медицинский университет<country>Россия</country></aff><aff xml:lang="en">Kuban State Medical University<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>13</day><month>10</month><year>2023</year></pub-date><volume>15</volume><issue>3</issue><fpage>44</fpage><lpage>50</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Городин В.Н., Мойсова Д.Л., Суркова А.Д., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Городин В.Н., Мойсова Д.Л., Суркова А.Д.</copyright-holder><copyright-holder xml:lang="en">Gorodin V.N., Moysova D.L., Surkova A.D.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.niidi.ru/jofin/article/view/1540">https://journal.niidi.ru/jofin/article/view/1540</self-uri><abstract><p>Все существующие в настоящее время исследования системы гемостаза при COVID-19 с помощью тромбоэластографии проведены на дельта-штамме SARS-CoV-2, при этом в литературе отсутствует информация о проведении подобных исследований у больных, инфицированных актуальным на сегодня штаммом омикрон.</p><sec><title>Цель</title><p>Цель:  определить  состояние   системы   гемостаза у госпитализированных больных COVID-19 (штамм омикрон) с помощью тромбоэластографии и оценить актуальность существующих рекомендаций по антикоагулянтной терапии.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы: тромбоэластография проведена 93 госпитализированным пациентам с COVID-19 в возрасте от 1 года до 88 лет, из них 66 больным (группа 1) – в 1-й день, 27 (группа 2) – на 2-й день. Группа контроля – 30 человек. Статистическая обработка результатов исследования проводилась с помощью программы Statistica 12.0 (Stat Soft, USA). Для сравнения независимой переменной более чем в 2 выборках выполнен многофакторный дисперсионный анализ ANOVA с расчетом критерия Краскела – Уоллиса. Для оценки взаимосвязей между непрерывными переменными определен коэффициент прямой линейной корреляции Спирмена (r).</p></sec><sec><title>Результаты</title><p>Результаты: у 53% пациентов отмечалась гипокоагуляция, у 31% – нормокоагуляция, у 16% – гиперкоагуляция. Гипокоагуляция чаще развивалась у пациентов пожилого возраста (61 [26–72] лет), гиперкоагуляция – у молодых пациентов (24,5 [7–37] лет). Рутинные методы оценки гемостаза не отражали его истинное состояние. Более высокие уровни фибриногена (4,5 [5,8–4] г/л) и D-димера (1,28 [0,5–2,77] мкг/мл) отмечались у пациентов из группы нормокоагуляции. Выявлена статистическая тенденция к росту уровня амилазы при повышении коагуляционных свойств крови.</p></sec><sec><title>Заключение</title><p>Заключение: при раннем поступлении нетяжелых больных с COVID-19 в стационар преобладают нормо- и гипокоагуляция. Пациентам пожилого и старческого возраста не рекомендуется назначать антикоагулянты без выполнения тромбоэластографии. Необходимо уточнить рекомендации по назначению антикоагулянтов госпитализированным больным и шире использовать тромбоэластографию в диагностике нарушений гемостаза.</p></sec></abstract><trans-abstract xml:lang="en"><p>All currently existing studies of the hemostasis system  in COVID-19 using thromboelastography (TEG) were performed on the delta strain of SARS-CoV-2, while there is no information in the literature on conducting such studies in patients infected with the current omicron strain.</p><sec><title>Research objective</title><p>Research objective. To determine the state of the hemostasis system in hospitalized patients with COVID-19 (omicron strain) using TEG. To assess the relevance of existing guidelines on anticoagulant therapy.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. TEG was performed in 93 hospitalized patients with COVID-19 aged 1 to 88 years, of which 66 patients (group 1) on the first day and 27 patients (group 2) – on the second day. For comparison with the parameters of healthy volunteers, a sample of 30 people was formed. Data analysis was performed using the Statistica, version  12 (StatSoft, USA). To compare the independent variable in more than two samples, a multivariate ANOVA analysis of variance was performed with the calculation of the Kruskal-Wallis test. To assess the relationships between continuous variables, the Spearman direct linear correlation coefficient (r) was determined.</p></sec><sec><title>Results</title><p>Results. 53% of patients had hypocoagulation, 31% had normocoagulation, and 16% had hypercoagulation. Elderly patients (61 [26–72]) more often have developed hypocoagulation. Young patients (24.5 [7–37]) more often have developed hypercoagulation. Routine methods for assessing hemostasis did not reflect its true state. Higher levels of fibrinogen (4.5 [5.8–4] g/l) and D-dimer (1.28 [0.5–2.77] µg/ ml) were observed in patients from the group with normocoagulation. Was revealed a statistical tendency towards an increase in the level of amylase when there was an increase in the coagulation properties of the blood.</p></sec><sec><title>Conclusion</title><p>Conclusion. With the current course of COVID-19 and early admission of non-severe patients to the hospital, normocoagulation and hypocoagulation predominate. Elderly and senile patients are not recommended to prescribe anticoagulants without TEG. It is necessary to specify the recommendations for prescribing anticoagulants to hospitalized patients. For the diagnosis of hemostasis disorders expand application of TEG.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>штамм омикрон</kwd><kwd>гемостаз</kwd><kwd>тромбоэластография</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>omicron strain</kwd><kwd>hemostasis</kwd><kwd>thromboelastography</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Maatman T.K., Jalali F., Feizpour C., Douglas A., 2nd, McGuire S.P., Kinnaman G., et al. Routine venous thromboembolism prophylaxis may be inadequate in the hypercoagulable state of severe coronavirus disease 2019. Crit Care Med. 2020;48:e783–e790.</mixed-citation><mixed-citation xml:lang="en">Maatman T.K., Jalali F., Feizpour C., Douglas A., 2nd, McGuire S.P., Kinnaman G., et al. Routine venous thromboembolism prophylaxis may be inadequate in the hypercoagulable state of severe coronavirus disease 2019. Crit Care Med. 2020;48:e783–e790.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Wright F.L., Vogler T.O., Moore E.E., Moore H.B., Wohlauer M.V., Urban S., et al. Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection. J Am Coll Surg. 2020;231:193–203.e1.</mixed-citation><mixed-citation xml:lang="en">Wright F.L., Vogler T.O., Moore E.E., Moore H.B., Wohlauer M.V., Urban S., et al. Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection. J Am Coll Surg. 2020;231:193–203.e1.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kruse J.M., Magomedov A., Kurreck A., Münch F.H., Koerner R., Kamhieh-Milz J., et al. Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis. Crit Care. 2020;24:676.</mixed-citation><mixed-citation xml:lang="en">Kruse J.M., Magomedov A., Kurreck A., Münch F.H., Koerner R., Kamhieh-Milz J., et al. Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis. Crit Care. 2020;24:676.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Chaudhary R., Kreutz R.P., Bliden K.P., Tantry U.S., Gurbel P.A. Personalizing antithrombotic therapy in COVID-19: role of thromboelastography and thromboelastometry. Thromb Haemost. 2020;120:1594–1596.</mixed-citation><mixed-citation xml:lang="en">Chaudhary R., Kreutz R.P., Bliden K.P., Tantry U.S., Gurbel P.A. Personalizing antithrombotic therapy in COVID-19: role of thromboelastography and thromboelastometry. Thromb Haemost. 2020;120:1594–1596.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hartmann J., Ergang A., Mason D., Dias J.D. The role of teg analysis in patients with COVID-19-associated coagulopathy: a systematic review. Diagnostics (Basel) 2021;11:172.</mixed-citation><mixed-citation xml:lang="en">Hartmann J., Ergang A., Mason D., Dias J.D. The role of teg analysis in patients with COVID-19-associated coagulopathy: a systematic review. Diagnostics (Basel) 2021;11:172.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bareille M., Hardy M., Douxfils J., Roullet S., Lasne D., Levy J.H., et al. Viscoelastometric testing to assess hemostasis of COVID-19: a systematic review. J Clin Med. 2021;10:1740.</mixed-citation><mixed-citation xml:lang="en">Bareille M., Hardy M., Douxfils J., Roullet S., Lasne D., Levy J.H., et al. Viscoelastometric testing to assess hemostasis of COVID-19: a systematic review. J Clin Med. 2021;10:1740.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kim S.M., Kim S.I., Yu G., Kim J.S., Hong S.I., Chae B., et al. Role of thromboelastography in the evaluation of septic shock patients with normal prothrombin time and activated partial thromboplastin time. Sci Rep. 2021;11</mixed-citation><mixed-citation xml:lang="en">Kim S.M., Kim S.I., Yu G., Kim J.S., Hong S.I., Chae B., et al. Role of thromboelastography in the evaluation of septic shock patients with normal prothrombin time and activated partial thromboplastin time. Sci Rep. 2021;11</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kim S.M., Kim S.I., Yu G., Kim Y.J., Kim W.Y. Which septic shock patients with non-overt DIC progress to DIC after admission? Point-of-care thromboelastography testing. Shock. 2022;57:168–174.</mixed-citation><mixed-citation xml:lang="en">Kim S.M., Kim S.I., Yu G., Kim Y.J., Kim W.Y. Which septic shock patients with non-overt DIC progress to DIC after admission? Point-of-care thromboelastography testing. Shock. 2022;57:168–174.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hartmann J., Hermelin D., Levy J.H. Viscoelastic testing: an illustrated review of technology and clinical applications. Res Pract Thromb Haemost 2022 Dec 27;7(1):100031. doi: 10.1016/j.rpth.2022.100031.</mixed-citation><mixed-citation xml:lang="en">Hartmann J., Hermelin D., Levy J.H. Viscoelastic testing: an illustrated review of technology and clinical applications. Res Pract Thromb Haemost 2022 Dec 27;7(1):100031. doi: 10.1016/j.rpth.2022.100031.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ярец, Ю.И. Тромбоэластография: основные показатели, интерпретация результатов / Ю.И. Ярец. – Гомель: ГУ «РНПЦ РМиЭЧ», 2018.</mixed-citation><mixed-citation xml:lang="en">Yarets Y.I. Thromboelastography: main indicators, interpretation of results / – Gomel, 2018.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Макацария А.Д. Тромботический шторм, нарушения гемостаза и тромбовоспаление в условиях COVID-19 / А.Д. Макацария [и др.] // Акушерство, Гинекология и Репродукция. – 2021. –15 (5). – С. 499–514.</mixed-citation><mixed-citation xml:lang="en">Makatsariya A.D., Slukhanchuk E.V., Bitsadze V.O., Khizroeva J.K., Tretyakova M.V., Shkoda A.S., Akinshina S.V., Makatsariya N.A., Tsibizova V.I., Gris J., Elalamy I., Ay С., Grandone E. Thrombotic storm, hemostasis disorders and thromboinflammation in COVID-19. Obstetrics, Gynecology and Reproduction. 2021;15(5):499-514.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Городин, В.Н. Роль полиморфизма генов системы гемостаза в патогенезе COVID-19 / В.Н. Городин [и др.] // Инфекционные болезни. – 2021. – № 19 (2). – С. 16–26.</mixed-citation><mixed-citation xml:lang="en">Gorodin V.N., Moysova D.L., Zotov S.V., Vanyukov A.A., Podsadnyaya A.A., Tikhonenko Yu.V. Role of polymorphisms of genes involved in hemostasis in COVID-19 pathogenesis. Infekc. bolezni (Infectious diseases). 2021; 19(2): 16–26.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)», версия 17 (14.12.2022).</mixed-citation><mixed-citation xml:lang="en">Temporary guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)”, version 17 (14.12.2022).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
